Compound 5 shows remarkable inhibitory activity against BET in vitro, and excellent anti-tumor activity against a variety of solid tumors and hematological malignancies in vivo, including breast cancer, nasopharyngeal carcinoma, lung cancer, NMC, glioblastoma, neuroblastoma, acute myeloid leukaemia, and lymphoma [50–52]. This evidence concerns the gene DNER and hematologic disorder.